Polyactin A increases CD4⁺ T-cell counts in HIV-infected individuals with insufficient immunologic response to highly active antiretroviral therapy

Abstract

We conducted a study to determine whether an immunomodulator, polyactin A, is able to enhance the immunologic response in patients with insufficient immunologic response to highly active antiretroviral therapy. From 783 patients, 48 were eligible and were randomly assigned to an experimental group receiving polyactin A for 3 months or a control group. CD4(+) T-cell counts in the experimental group increased from 201 ± 31 to 228 ± 38 cells/µl after treatment (p < 0.001). CD4(+) T-cell counts in the control group and CD8(+) T-cell counts and CD4(+)/CD8(+) ratios in both groups did not differ significantly between baseline and month 3. The experimental group had a higher CD4(+) T-cell count than the control group at month 3 (228 ± 38 versus 205 ± 35, p < 0.05). Our work demonstrated that polyactin A can increase CD4(+) T-cell counts in patients with insufficient immunologic response to highly active antiretroviral therapy, but further studies are required to determine its clinical benefits.

CD8 + T‐cell percentage increases in diffuse large B‐cell lymphoma patients receiving mannatide combined with standard regimens

“…MT has been developed and used as an immunomodulator and adjuvant treatment for immunocompromised diseases, such as cancer and chronic hepatitis B, in China for over 30 years. 7 MT modulates the immune function by a variety of pathways. Previous studies have suggested the effect of MT on CD4 + T-cell count and CD4 + /CD8 + ratio.…”

“…Mannatide (MT), also known as a‐Polyactin or Polyactin A (PAA), is a heteropolysaccharide isolated from fermentation broth of buccalalpha‐haemolytic streptococcus strain No.33. MT has been developed and used as an immunomodulator and adjuvant treatment for immunocompromised diseases, such as cancer and chronic hepatitis B, in China for over 30 years 7 . MT modulates the immune function by a variety of pathways.…”

“…MT modulates the immune function by a variety of pathways. Previous studies have suggested the effect of MT on CD4 + T‐cell count and CD4 + /CD8 + ratio 7,8 . In this study, we retrospectively examined the effect of MT on the T‐cell subtypes in DLBCL patients.…”

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59

“…33.1. PA is an immunomodulator and adjuvant that has been used for the treatment of impaired immunity, including cancer and chronic hepatitis B, in China for more than 30 years [16, 17]. A previous study showed that PA improved the production of the antibodies against hepatitis B surface antigen (anti-HBs) after hepatitis B virus vaccine immunization [18].…”

Polyactin A can increase CD4+T cell counts in HIV-infected individuals with insufficient immunologic response to HAART: is it a reality?

“…1 Recently, with great interest we read the article by Su et al. titled “Polyactin A increases CD4 + T cell counts in HIV-infected individuals with insufficient immunologic response to highly active antiretroviral therapy”, 2 which was a prospective, randomized, open-label, parallel clinical trial study. This is commendable, however there were few studies on the essential problem with Polyactin A (PAA).…”